Brimonidine Tartrate/Ripasudil hydrochloride

酒石酸溴莫尼定/利舒地尔盐酸盐

Report date: 2025/04/07 15:39:18

Base Information

Drug NameBrimonidine Tartrate/Ripasudil hydrochloride
Drug Alias NameK-232
ClassificationSmall molecules
Mechanisms of ActionAdrenergic receptors alpha-2 agonistsRho-associated protein kinase 2 inhibitorsRho-associated protein kinase 1 inhibitors
TargetsAdrenergic receptors alpha-2Rho-associated protein kinase 2Rho-associated protein kinase 1
Therapy Area/IndicationsGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsYes Brimonidine TartrateRipasudil hydrochloride
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesKowa Dental Health Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKowa Dental Health Co Ltd
Inactive CompaniesN/A
Active IndicationsGlaucomaOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A